Introduction
[ 18 
F ]
FDDNP has recently been introduced [1] as a positron emission tomography (PET) ligand for in vivo imaging of amyloid plaques and neurofibrillary tangles in the human brain. Plaques and tangles are thought to be the hallmark of Alzheimer's disease (AD) [2] , and early in vivo detection of these neuropathological lesions could be an important step in evaluating future treatment strategies for AD.
So far, only a few methods for quantification of [
18 F] FDDNP have been evaluated, such as residence time within a cerebral region relative to that in pons [3] , standardized uptake value (SUV) [4] , distribution volume ratio (DVR) [4] obtained with Logan analysis [5] using cerebellum as reference region, and several simplified reference tissue-based methods [6] also using cerebellum as reference region. Using Logan analysis, Kepe et al. [7] recently reported increased levels of [ 18 
F]
FDDNP binding in neocortical regions compared with that in cerebellum in AD patients, whereas no difference in uptake between cerebellum and other regions was found in healthy controls (HC). In addition, Small et al. [8] found that global DVR values in HC were lower than in patients with mild cognitive impairment (MCI), which in turn were lower than in AD subjects. However, arterial sampling was not used in any of these studies. Arterial sampling is considered to be the gold standard, especially if pathological changes may also affect reference regions.
The purpose of the present study was to investigate which pharmacokinetic model could best be used for quantitative analysis of [ 18 F]FDDNP studies. To this end, both simulated and clinical [ 18 F]FDDNP data were used. Data were analyzed using various compartmental models based on plasma [9] and reference tissue [10] [11] [12] input data. In addition, a plasma input model was evaluated, which accounted for uptake of labeled metabolites in the brain. Finally, standard uptake value ratios with cerebellum (SUV r ) were investigated.
Methods

Scanning Protocol
Clinical data were derived from ongoing patient studies consisting of 12 subjects (six HC, three MCI [13] , and three AD) with ages ranging from 58 to 72 years. Mean age (±SD) was 66±5, 68±4, and 63±6 for HC, MCI, and AD, respectively. AD patients were diagnosed with probable AD meeting NINCDS-ADRDA criteria [14] . The study was approved by the Medical Ethics Committee of the VU University Medical Centre, and each subject gave written informed consent prior to inclusion in the study. Clinical results are beyond the scope of the present study and will be reported elsewhere.
As part of the study protocol, each subject first underwent a T1-weighted magnetic resonance imaging (MRI) scan using a 1.5-T SONATA scanner (Siemens Medical Solutions, Erlangen, Germany). This MRI scan was performed to exclude anatomical abnormalities and for co-registration and segmentation purposes.
PET studies were performed using an ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville, USA). The characteristics of this scanner have been described previously [15] . First, a 10-min transmission scan in 2D acquisition mode was performed. This scan was used to correct the subsequent emission scan for tissue attenuation. Next, a dynamic emission scan in 3D acquisition mode was performed following bolus injection of 168±8 MBq [
18 F] FDDNP [16] . This dynamic emission scan consisted of 23 frames (1×15, 3×5, 3×10, 2×30, 3×60, 2×150, 2×300, 7×600 s) with a total scan duration of 90 min. All frames were reconstructed using FORE+ 2D filtered back projection [17] and a Hanning filter with a cutoff of 0.5 times the Nyquist frequency. Reconstructions included all standard corrections, such as normalization, and decay, dead time, attenuation, randoms, and scatter [18] corrections.
The protocol also included continuous arterial sampling, starting 2 min prior to injection and continuing up to 60 min, using a dedicated online detection system [19] . In addition, at set times (5, 10, 20, 40 , and 60 min post-injection), arterial sampling was interrupted briefly for the withdrawal of discrete arterial samples. After each sample, the arterial line was flushed with heparinized saline in order to avoid clotting within the line. Finally, two manual samples were withdrawn at 75 and 90 min post-injection.
Arterial blood samples were used to determine plasma and whole blood radioactivity concentrations using a well counter cross calibrated against the PET scanner [20] . In addition, plasma parent tracer and metabolite concentrations were determined using solid phase extraction combined with high-performance liquid chromatography technology and equipped with off-line radioactivity detection [21] . An arterial whole blood curve was obtained by correcting the online sampler curve for decay, removing the flushing periods, and calibrating against the discrete (whole blood) sample data. Finally, a metabolite-corrected plasma curve was derived from this whole blood curve using both plasma to whole blood ratios and metabolite fractions obtained from the manual blood samples. To this end, the total fraction of labeled metabolites as function of time was fitted to a Hill-type function [22] . This function provided more accurate fits than other functions such as multi-exponentials. Arterial blood sampling was not available for six subjects (three HC and three MCI). Data from these subjects were only used for investigating reference tissue models.
Image Analysis
De-skulled T1-weighted MRI scans [23] were co-registered [24, 25] with a summed PET image (frames 3-12, 25 s-5 min post-injection). This summed PET image resembles a flow image, thereby maximizing cortical information. Time-activity curves were then generated using MR-based automatic delineation of regions of interest (ROI), as described by Svarer et al. [26] . For the purpose of the present study, only TACs from 17 regions (cerebellum, orbital frontal cortex, medial inferior frontal cortex, anterior cingulate cortex, thalamus, insula, caudate, putamen, superior temporal cortex, parietal cortex, medial inferior temporal cortex, superior frontal cortex, occipital cortex, sensory motor cortex, posterior cingulate cortex, enthorinal cortex, hippocampus), all averaged over left and right hemispheres, were analyzed. These anatomical regions were small and defined in gray matter only, thereby minimizing signal dilution due to partial volume effects as much as possible.
Kinetic Analyses of Clinical Data
Clinical data were analyzed using conventional plasma input and reference tissue-based algorithms [9] . As there is some concern that labeled [
18 F]FDDNP metabolites might cross the blood-brain barrier [27, 28] , additional analyses were performed using a plasma input model accounting for metabolites entering the brain. In addition, average regional activity concentration ratios with the reference region (SUV r ) were derived over the time intervals of 40-60, 60-90, and 80-90 min after injection. For all reference tissue models and SUV r cerebellar gray matter was used as reference region based on its relatively low levels of amyloid and neurofibrillary tangles [2] .
Five different conventional compartmental models were evaluated: single-tissue (1T2k), two-tissue irreversible (2T3k) and twotissue reversible (2T4k) plasma input models, and simplified (SRTM) [12] and full (FRTM) [10, 11] 
À 1Þ [11] . The latter approach will be indicated by 2T4k i . Based on the possibility of metabolites entering the brain [27, 28] , also a modified 2T4k model was used. This model included an additional (parallel) single-tissue compartment for labeled metabolites (2T1M, Fig. 1 ). The metabolite input curve was based only on polar metabolites and ignores the minor fraction of other metabolites. The direct binding potential
BP 2T1M ND
for this model was defined as k 3 /k 4 ( Fig. 1) , and the volumes of distributions, V T and V Tm , were defined as
and K 1m /k 2m , respectively. Similar to 2T4k 
Clinical Studies
Clinical results were evaluated in several ways. First, for all compartmental models (SRTM, FRTM, 1T2k, 2T3k, 2T4k, 2T1M, and 2T1M fvtm ), fitted TACs were evaluated using the Akaike criterion. Next, where possible, BP ND values were estimated both directly and indirectly using V T ratios with cerebellum (i.e., 2T4k 
Simulation Studies
Conventional Simulations Simulated time-activity curves (TACs) for target and reference regions were generated using a typical [ Kinetic parameters were based on typical 2T4k parameters obtained from clinical data. Default parameters for simulated reference and target tissue TACs are given by R1 and T1, respectively, as listed in Table 1 . Target tissue parameters were varied with respect to binding potential (BP 2T4k ND and BP 2T4k i ND : T2-T5), fractional blood volume (V b : T6, T7), and delivery (K 1 : T8-T15). One hundred TACs were generated for each run and noise was added to simulate an average noise level of 7.5% coefficient of variation (COV). Noise simulation was based on clinically derived typical values of total scanner true counts, frame lengths, and decay correction factors. A detailed description of the noise simulation used is given in [29] .
Simulated data were analyzed using conventional models as described above (1T2k, 2T3k, 2T4k, SRTM, FRTM, and 2T4k ) are rate constants, describing exchange of parent between plasma and tissue; k 3 and k 4 are rate constants (min
), describing exchange of parent between free and bound compartments; K 1m (ml·cm
) and k 2m (min
) are rate constants, describing exchange of labeled metabolites between plasma and tissue. Table 1 . Kinetic parameters used to generate reference (R) and target (T) tissue time activity curves (TAC) In addition to BP ND , in metabolite simulations, also V T values were estimated using 2T4k and the 2T1M fvtm models. Bias in estimated V T for the 2T4k model was defined as 100
Results
Time-Activity Curves
Typical parent [ 18 F]FDDNP and polar metabolite plasma curves are shown in Fig. 2a and typical time-activity curves for cerebellum and frontal cortex in Fig. 2b (Fig. 3) . The polar metabolites are composed of N-dealkylated fragments with similar chromatogram retention times as primarily fluoroethanal and with a smaller fractions of fluoroacetic acids [28] . Fig. 4 show typical fits using various compartmental models. In general, poor fits were seen for the 1T2k model (Fig. 4a) . Metabolite models showed slightly better fits (Fig. 4b) than all conventional models (Fig. 4a) . Good fits were seen for the reference tissue models (Fig. 4c) . Similarly, the Akaike criterion gave preference to 2T1M models above other plasma input models (2T1M fvtm 37.3%, 2T1M 31.7%, 2T4k 26.2%, 2T3k 4.8%, and 1T2k 0% preference, respectively). With respect to reference tissue models, the Akaike criterion had strong preference for SRTM (88%).
Clinical Studies
Average values of the various parameters, together with observed range, for 2T4k, 2T1M, and SRTM models are given in Tables 3, 4 , and 5 for typical AD regions, i.e., for regions previously shown to be involved in AD [8] . These regions were used in order to accurately estimate typical kinetic parameters for AD subjects, as the latter parameter estimates were used in the simulations. Fig. 5 shows high correlation (R 2 =0.95) between K 1m and k 2m values from the 2T1M model over all regions and subjects, indicating an almost constant V T for metabolites. Table 6 shows correlation coefficients obtained from linear regression analyses of various outcome measures with and are binding potentials estimated directly and indirectly using the metabolite model, respectively. The indirect calculation of BP ND was performed using target to reference volumes of distribution ratios. K 1m is a rate constant and V Tm the volume of distribution for the metabolites. During all simulations, k 4 (0.099 min −1 ) and K 1 /k 2 (2.4) were fixed, and same, the K 1m and k 2m were used in reference and target tissues BP SRTM ND . As expected, high correlation was found between BP ND estimates of SRTM and FRTM (R 2 =0.99). In addition, good correlation was obtained for SUV r over 40-60 min (R 2 =0.93). Note that the 2T1M i models, i.e., including a compartment for metabolites entering the brain, correlated better with SRTM than the conventional 2T4k i model (Table 6 and Fig. 6 ).
Simulation Studies
Conventional Simulations In general, SRTM produced better fits than FRTM according to the Akaike criterion (∼85% preference). According to the same criterion, 2T4k showed better fits than both 1T2k and 2T3k in all simulations (∼96% preference). At lower K 1 values, however, preference for 2T4k reduced in favor of 2T3k (max. 33% preference for 2T3k). Visual inspection showed poor fits for the 1T2k model, similar to what was seen in clinical fits, and therefore, it was excluded from further evaluation.
When simulating different levels of binding the 2T4k model (direct estimation of BP ND ) showed good overall accuracy (5% bias BP ND ), but mediocre precision (24% COV BP ND ). Results for reference tissue-based models, including SUV r , are summarized in Table 7 . In general, all reference tissue-based methods showed increased bias at lower levels of binding, but results were more stable at higher levels. Therefore, bias estimates were averaged only over the stable part, i.e., for BP (Table 7) . Average bias ( derived BP ND due to changes in simulated V b were smaller than 5% for all compartmental models. For SUV r methods, bias (±COV) in approximated BP ND (i.e., SUV r −1) depended on the actual time interval used and changed from 21±16% to 10±18%, from 30±22% to 28±21%, and from 31±41% to 34±45% for SUV r40-60 , SUV r60-90 , and SUV r80-90 , respectively, when varying V b of the target region from 0.025 to 0.075.
Delivery differences affected all compartmental methods, including plasma input models. For the direct 2T4k model, bias in BP ND varied from 10% to −2% when varying K 1 of the target region from 0.212 to 0.496. Results for indirect 2T4k and SRTM are shown in Fig. 7 . Results from FRTM are not included, as BP ND bias was as high as 250%. Bias in BP ND (±COV), based on SUV r −1, ranged from −27±18% to 3±17%, from 25±20% to −3±18%, and from 48±36% to −7 ±39% for SUV r40-60 , SUV r60-90 , and SUV r80-90 , respectively, when varying K 1 of the target region from 0.212 to 0.496. Metabolite Simulations Metabolite simulations were limited to 2T4k, 2T1M fvtm , and SRTM. SRTM provided the most precise estimation of BP ND over the range of simulated K 1m with a COV of 4.0±0.4%. Although there was a strong negative bias (−42±7%) for SRTM, it was very constant Fig. 4 . Decay corrected frontal cortex gray matter time-activity curve from an AD subject (=data) with fits using a conventional plasma input, b metabolite, and c reference tissue models. 
BP
SRTM ND
is the binding potential estimated using the simplified reference tissue model (Fig. 8a) . 2T 1M i fvtm provided a more accurate estimate of BP ND (5±7% bias), but precision (COV of 37±20%) was much poorer than for SRTM (Fig. 8a) . 2T1M fvtm , 2T4k, and 2T4k i provided lower precision and higher bias in estimated BP ND over the range of simulated K 1m (Fig. 8a, b) . However, V T estimates with the 2T1M fvtm model were much more accurate and had higher precision (Fig. 8c) .
Simulations over a range of different binding levels showed strong negative bias (−46±4% with COV of 7±6%) for SRTM, but again, resulting BP ND estimates were the most stable amongst all models tested (Fig. 9a) . Similarly, most accurate results were obtained with indirect 2T1M fvtm (Fig. 9a) . Precision of both SRTM and 2T 1M i fvtm improved with increasing BP ND . BP ND estimates obtained with 2T1M fvtm , 2T4k, and 2T4k
i were not precise and strongly biased (Fig. 9) . Finally, Fig. 10a shows nearly linearly increasing (negative) bias in BP ND obtained with SRTM for increasing V Tm . In contrast, Fig. 10b illustrates that this bias was independent of K 1m for K 1m 90.1.
Discussion
Clinical Studies
Due to rapid plasma clearance and metabolism [
18 F]FDDNP scans, it proved to be difficult to obtain reliable measurements of metabolite fractions at later time points. As a result, only incomplete plasma data were available for six of the subjects, and data from these subjects were only used for evaluation of reference tissue models. Although only six subjects with complete plasma input data remained, this BP SRTM ND is the binding potential estimated using the simplified reference tissue model Fig. 5 . Correlation between metabolite influx (K 1m ) and efflux (k 2m ) rate constants for clinical [ 18 F]FDDNP data from several regions of interests and subjects. These rate constants were obtained using a modified two-tissue reversible model, including an additional single-tissue compartment for metabolites. In the case of SUV r methods, SUV r −1 was taken as an estimate of BP ND a NA indicates poor correlation, i.e., R 2 G0.10 seems to be sufficient for this initial evaluation of quantitative (plasma input) models. Clearly, however, the difficulties in obtaining reliable plasma metabolite data should be taken into account when selecting a method for routine clinical studies. Clinical [ 18 F]FDDNP data were analyzed using conventional models, models correcting for possible metabolites entering the brain, and activity ratios. Clearly, due to the very nature of clinical data, absolute statements about accuracy and precision cannot be given. Therefore, the various methods were compared using the Akaike criterion. In addition, resulting BP ND values were compared with SRTM, as this model showed stable results during simulations.
On the basis of the Akaike criterion, plasma input models with a compartment for metabolites were preferred over conventional plasma input models, and SRTM was preferred over FRTM. Good correlations with SRTM were obtained only for FRTM, SUV r40-60 , and plasma input models that included a compartment for metabolites entering the brain, such as 2T1M i and 2T1M i fvtm (Fig. 6 ). 18 F] FDDNP data were generated using the metabolite plasma input model (2T1M) with variable metabolite influx rates (K 1m ).
For most other methods, correlations with SRTM were poor (R 2 G0.1). Specifically, in the case of the metabolite models, somewhat large values were seen for the micro parameters K 1m and k 2m (Fig. 5) . However, the majority of observed K 1m values are below 0.5 (many overlapping data at lower K 1m ), and K 1m and k 2m are well correlated. The higher K 1m and k 2m values are possibly the result of noise, as the higher values for K 1m and k 2m were generally seen for the smallest ROIs used. Moreover, the relative slow in-grow of metabolites, i.e., the metabolite input function shows a slow increase rather than a sharp peak, makes estimation of individual micro-parameters less precise. Note, however, that the macro-parameter V Tm is reasonably stable across anatomical regions and subjects.
Observed improvements in fits and correlations for models that incorporate a labeled metabolite compartment, together with the reasonably constant V Tm , suggest that metabolites enter the brain. This is in line with a previous assessment using multi-input spectral analysis [27] and initial animal studies where labeled metabolites of [
18 F] FDDNP were injected [28] . Additional studies are, however, needed to confirm whether this is indeed the case.
Simulation Studies
The standard 2T4k plasma input model was not a good model for estimating the level of specific [ 18 F]FDDNP binding directly (i.e., as defined by k 3 /k 4 ). Firstly, although BP ND bias calculated relative to total binding potential showed good accuracy, it only had mediocre precision. Secondly, at lower regional delivery (=K 1 ) levels, its bias was sensitive to the actual value of K 1 . This increased sensitivity to K 1 is related to the kinetics of [ 18 F]FDDNP, which, for a normal level of binding in regions with low delivery, are relatively slow. Under those conditions, within the time frame of a scan, tracer kinetics are best described by an irreversible compartment model, which is illustrated by the increased preference for the 2T3k model according to the Akaike criterion. The 2T1M fvtm model did not provide accurate estimates of (direct) BP ND in the metabolite simulations (Figs. 8b and 9b) . Although data were simulated using the same model, BP ND was very sensitive to noise as a result of the large number of fit parameters. However, V T estimates obtained with the 2T1M fvtm model were less sensitive to noise and provided highly accurate and precise V T values (Fig. 8c) .
For plasma input models, more accurate and precise results were obtained with indirect estimates of BP ND (2T4k i and 2T 1M i fvtm ) than with their direct counterparts (2T4k and 2T1M fvtm ), especially in the case of metabolite simulations. In most cases, these indirect methods showed lower bias than BP SRTM ND . This higher accuracy of 2T4k i (in conventional simulations) and 2T 1M i fvtm (in metabolite simulations) was, however, accompanied with lower precision compared with BP SRTM ND . SRTM was better than FRTM, both in terms of bias and COV. In addition, in the majority of the simulations, it was preferred by the Akaike criterion. SRTM results were comparable in conventional and metabolite simulations. If no metabolites entered the brain, SRTM-derived BP ND showed a constant negative bias, although it was affected by changes in delivery. On the other hand, when polar metabolites entered the brain, SRTM showed increasing negative bias with increasing V Tm . However, clinical data showed an overall constant V Tm (Fig. 5 ). This indicates that variable bias in SRTM-derived BP ND due to variability in V Tm will be limited. Simulations showed that for V Tm fixed to the clinical estimated value (V Tm =0.6), this bias also was not sensitive to metabolite influx (Fig. 10b, K 1m 90 .01, BP ND bias ∼−46%). Furthermore, the bias found in these simulations could be related to the slope between BP SRTM ND versus BP 2T1M i fvtm ND (slope=2.59, Table 6 ; 100%× (1/2.59)=39%) for the clinical studies, indicating a relatively constant metabolite contribution in practice. Thus, SRTM seems to be a useful method, irrespective whether labeled metabolites enter the brain, provided that V Tm is relatively constant across the brain and between subjects, as actually suggested by the clinical results.
Among SUV r methods, over the range of simulated binding levels, only SUV r40-60 showed acceptable results, with much better accuracy (−1%) than SRTM (−12%). However, apart from a strong dependency on variations in delivery, SUV r results were also highly dependent on differences in blood volume fractions with only an acceptable accuracy for a specific time interval (SUV r60-90 ). In general, SUV r results varied widely between different time intervals which, together with the large uncertainties, indicate that this might not be the ideal method for clinical studies.
In general, SRTM showed best overall performance, although it showed some sensitivity to regional flow/ delivery differences. As expected, SRTM, like all other reference tissue-based models, showed larger biases at lower regional binding levels. Important advantages of SRTM were its overall high precision and a relatively constant bias in BP ND even in the presence of labeled metabolites. Although this bias was dependent on the actual value of V Tm , clinical data indicated that this was constant across the brain and among subjects.
General Considerations
Amyloid plaques (and neurofibrillary tangles) do not behave like neuroreceptors. They have complex structures with multiple affinity sites for [ 18 F]FDDNP. In addition, it is likely that access to amyloid sites will become more difficult with increasing plaque size [30] . Consequently, use of receptor-ligand models to assess amyloid load might provide an increasing underestimation with increasing load. In addition, quantification might be compromised by the possibility of labeled metabolites entering the brain, especially since the fraction of labeled (polar) metabolites in blood is high due to rapid metabolism of [ 18 F]FDDNP. Nevertheless, [ 18 F]FDDNP may still be of value if a difference between MCI and healthy controls can be demonstrated, and it might be used to study pathological effects as a function of disease severity/progression [8] . In addition, at early stages, a stable receptor-ligand model is likely to provide a reasonable quantitative estimate of the pathological changes associated with AD and could therefore be an important tool in evaluating effects of therapy. Clearly, given its relatively small specific signal, the value of [ 18 F]FDDNP can only be determined by large comparative clinical studies, such as the one by Small et al. [8] . From the present study, it follows that such a comparison should preferably be performed using SRTM as method of analysis, as it showed high precision and constant bias across the brain and among subjects even when metabolites enter the brain.
Conclusion
SRTM outperformed other models, providing BP ND estimates with high precision. As clinical data indicated that the volume of distribution of labeled metabolites V Tm was constant across the brain and among subjects, bias in SRTM-derived BP ND will be constant and predictable. The main potential drawback is its sensitivity to variations in regional K 1 , although this did not appear to be a problem in the clinical studies.
